A Phase 4 interventional study of salbutamol aqueous solution and salbutamol pressurized metered dose inhaler in Asthma, sponsored by University of Saskatchewan. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by University of Saskatchewan · Phase 4, Interventional, and Treatment
The study will compare salbutamol reversibility of methacholine induced bronchoconstriction between a pressurized metered dose inhaler with a spacer versus nebulizer administration using a vibrating mesh nebulizer.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 16 is below the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →University of Saskatchewan is the lead sponsor of 237 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
200mcg of salbutamol will be delivered using a pressurized metered dose inhaler plus spacer
Drug: salbutamol pressurized metered dose inhaler
normal saline will be administered with a vibrating mesh nebulizer and 200mcg of placebo will be administered using a pressurized metered dose inhaler plus spacer
Other: placebo
200microliters of salbutamol will be administered using a vibrating mesh nebulizer
Drug: salbutamol aqueous solution
administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer
Lung function recovery
Maximal recovery in FEV1 and FVC (absolute volume and percent)
Time frame: up to 60 minutes post salbutamol administration
Time to lung function recovery
Area under the curve from start of salbutamol administration to time at which maximal recovery occurs
Time frame: 0-60 minutes
Heart rate
change in pulse after salbutamol administration
Time frame: 0-60 minutes
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Saskatchewan